Real‐world utility of early measurable residual disease assessments by multi‐parametric flow cytometry in adult patients with B‐lymphoblastic leukemia receiving Hyper‐CVAD induction chemotherapy

微小残留病 医学 肿瘤科 内科学 诱导化疗 化疗 多元分析 流式细胞术 白血病 免疫学
作者
Rithin Nedumannil,David Ritchie,Ashish Bajel,Ashley P. Ng,Simon Harrison,David Westerman
出处
期刊:European Journal of Haematology [Wiley]
卷期号:110 (2): 168-176
标识
DOI:10.1111/ejh.13890
摘要

Abstract Multi‐parametric flow cytometry (MFC) has a well‐established role in measurable residual disease (MRD) monitoring in patients with B‐lymphoblastic leukemia (B‐ALL). However, the optimal time‐point (TP) for early MRD testing and associated prognostic impact remain undefined in adult B‐ALL patients receiving Hyper‐CVAD induction chemotherapy. To evaluate the utility of MRD analysis after one cycle (TP1) in comparison to MRD analysis after two cycles (TP2) of induction treatment with Hyper‐CVAD chemotherapy, we studied 49 adult B‐ALL patients over a 10‐year period (2010–2020) who had available bone marrow samples for morphological and MFC MRD assessments at the two separate TPs. Median times to TP1 and TP2 relative to start of treatment were 21 and 45 days, respectively. When censored at transplant, achievement of MRD negativity at TP1 was not associated with a statistically significant improvement in either event‐free survival (EFS) ( p = .426) or overall survival (OS) ( p = .335) when compared to patients with MRD positivity. In contrast, achieving MRD negativity at TP2 was associated with a statistically significant improvement in both EFS ( p = ·005) and OS ( p = .047) over patients who remained MRD positive. Multivariate analysis demonstrated that KMT2A ‐rearrangement and MRD positivity at TP2 were the only significant predictors of outcome, correlating with worse EFS and OS. Therefore, in the absence of residual morphologic disease, MRD analysis after one cycle of Hyper‐CVAD induction chemotherapy did not provide additional benefit with regard to risk stratification or correlation with survival outcomes when compared to MRD testing after two cycles of Hyper‐CVAD in adult B‐ALL patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
飒飒完成签到,获得积分10
1秒前
RONG完成签到 ,获得积分10
1秒前
落落完成签到,获得积分10
2秒前
Yan完成签到 ,获得积分10
3秒前
3秒前
谨慎的凝丝完成签到 ,获得积分10
4秒前
雨洋完成签到,获得积分10
5秒前
chi完成签到 ,获得积分10
6秒前
还单身的湘完成签到,获得积分10
8秒前
fyjlfy完成签到 ,获得积分10
8秒前
深情安青应助Nayvue采纳,获得10
9秒前
研友_Y59785完成签到,获得积分0
9秒前
Xiaoxiao发布了新的文献求助10
10秒前
初初见你完成签到,获得积分10
17秒前
20秒前
思源应助淡淡月饼采纳,获得20
20秒前
dd完成签到 ,获得积分10
21秒前
Nayvue发布了新的文献求助10
25秒前
未来的幻想完成签到,获得积分10
27秒前
Kvolu29完成签到,获得积分10
28秒前
长理物电强完成签到,获得积分10
29秒前
若安在完成签到,获得积分10
30秒前
完美世界应助潘特采纳,获得10
31秒前
拼搏问薇完成签到 ,获得积分10
31秒前
单薄乐珍完成签到 ,获得积分0
34秒前
张静枝完成签到 ,获得积分10
34秒前
六步郎完成签到,获得积分10
34秒前
啊怙纲完成签到 ,获得积分10
36秒前
量子星尘发布了新的文献求助10
38秒前
scott_zip完成签到 ,获得积分10
39秒前
gxl完成签到,获得积分0
43秒前
xxx完成签到 ,获得积分10
46秒前
46秒前
努力生活的小柴完成签到,获得积分10
48秒前
50秒前
tangyong完成签到,获得积分10
52秒前
长安发布了新的文献求助10
52秒前
SucceedIn完成签到,获得积分10
53秒前
54秒前
57秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038184
求助须知:如何正确求助?哪些是违规求助? 3575908
关于积分的说明 11373872
捐赠科研通 3305715
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022